NCT02019121

Brief Summary

Investigators aim to retrospectively research patients undergoing renal transplants that received dexmedetomidine perioperatively to see if dexmedetomidine use protects renal function. Investigators hope to elucidate any association between renal transplant patients and perioperative dexmedetomidine administration, these include (but are not limited to) UOP, Cr/GFR, morbidity, mortality, in hospital complications and failure rate. Investigators will research both living and cadaveric renal transplants.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
797

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2013

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2013

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

November 5, 2013

Completed
2 months until next milestone

First Posted

Study publicly available on registry

December 24, 2013

Completed
6.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2020

Completed
Last Updated

July 11, 2022

Status Verified

July 1, 2022

Enrollment Period

6.3 years

First QC Date

November 5, 2013

Last Update Submit

July 5, 2022

Conditions

Renal Failure

Outcome Measures

Primary Outcomes (1)

  • Cr/GFR improvement, postoperative mortality/morbidity (within 30 days) and overall complications

    5 years

Secondary Outcomes (1)

  • Graft failure, length of hospital stay (LOS), length of ICU stay, re-admission rate, infections, pulmonary complications.

    5 years

Other Outcomes (1)

  • length of intubation time, and length of ventilation time

    5 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Renal transplant patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UC Davis Health System

Sacramento, California, 95817, United States

Location

Related Links

MeSH Terms

Conditions

Renal Insufficiency

Condition Hierarchy (Ancestors)

Kidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Officials

  • Hong Liu, M.D.

    University of California, Davis

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 5, 2013

First Posted

December 24, 2013

Study Start

October 1, 2013

Primary Completion

February 1, 2020

Study Completion

February 1, 2020

Last Updated

July 11, 2022

Record last verified: 2022-07

Locations

US(1)